AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39143826 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated tool for evaluating confirmed disability progression (CDP)
Number of subjects: 0
Study 39143826 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated tool for evaluating progression independent of relapse activity (PIRA)
Number of subjects: 0
Study 39144112 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Benzoate (NaB)
Number of subjects: 68
Study 39144112 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 68
Study 39144112 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 68
Study 39144343 — intervention group
Group type: EXPERIMENTAL
Intervention: Wedge resection
Number of subjects: 286
Study 39144362 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant immunochemotherapy with paclitaxel (albumin-bound) (260 mg/m2) and short-course radiotherapy
Number of subjects: 0
Study 39144362 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant immunochemotherapy with paclitaxel (albumin-bound) (260 mg/m2)
Number of subjects: 0
Study 39144777 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel enrichment strategy based on PANSS scores
Number of subjects: 0
Study 39144777 — intervention group
Group type: COMPARATOR
Intervention: Standard criteria for selecting patients
Number of subjects: 0
Study 39144826 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine and nab-paclitaxel
Number of subjects: 32
Study 39145150 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-frequency TENS (2 Hz/80 Hz) administered using specially designed pants
Number of subjects: 30
Study 39145150 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-frequency TENS (2 Hz/80 Hz)
Number of subjects: 30
Study 39145294 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy-assisted overground Trexo use
Number of subjects: 0
Study 39145517 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral energy and protein supplements
Number of subjects: 11926
Study 39145520 — intervention group
Group type: COMPARATOR
Intervention: Daily oral iron supplementation
Number of subjects: 48971
Study 39145520 — intervention group
Group type: COMPARATOR
Intervention: Iron + folic acid supplementation
Number of subjects: 48971
Study 39145678 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole Lauroxil (1-Day Regimen)
Number of subjects: 0
Study 39145678 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole Lauroxil (21-Day Regimen)
Number of subjects: 0
Study 39145678 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39145700 — intervention group
Group type: EXPERIMENTAL
Intervention: Potential disease-modifying therapy for LMNA-related DCM (details not specified)
Number of subjects: 77
Study 39145733 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac MRI-derived aortic stiffness
Number of subjects: 48
Study 39145733 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 48
Study 39145955 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterus transplant (from 18 living donors and 2 deceased donors), surgically placed in an orthotopic position with vascular anastomoses to the external iliac vessels, with immunosuppression until the transplanted uterus was removed after 1 or 2 live births or after graft failure.
Number of subjects: 20
Study 39145955 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterus transplant
Number of subjects: 20
Study 39145962 — intervention group
Group type: EXPERIMENTAL
Intervention: Lazertinib, 240 mg, once daily
Number of subjects: 40
Study 39145961 — intervention group
Group type: EXPERIMENTAL
Intervention: POC salivary oral rinse test
Number of subjects: 172
Study 39145961 — intervention group
Group type: EXPERIMENTAL
Intervention: CD44 and TP levels
Number of subjects: 172
Study 39145984 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-widefield (UWF) imaging
Number of subjects: 785
Study 39145984 — intervention group
Group type: COMPARATOR
Intervention: 7-field (7F) imaging
Number of subjects: 785
Study 39145984 — intervention group
Group type: EXPERIMENTAL
Intervention: Both UWF and 7F imaging
Number of subjects: 785
Study 39145984 — intervention group
Group type: EXPERIMENTAL
Intervention: UWF-global area assessment
Number of subjects: 785
Study 39146010 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory white noise (78 dB)
Number of subjects: 97
Study 39146010 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual white noise (25% and 50%)
Number of subjects: 97
Study 39146010 — intervention group
Group type: COMPARATOR
Intervention: No noise stimulation
Number of subjects: 97
Study 39146062 — intervention group
Group type: EXPERIMENTAL
Intervention: Very brief web-based intervention focused on protective behavioral strategies (PBS)
Number of subjects: 0
Study 39146062 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39146072 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-leadership training
Number of subjects: 0
Study 39146072 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 39146178 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligofructose-enriched inulin (OEI) prebiotic (4 g, 3 times a day)
Number of subjects: 27
Study 39146178 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 g of maltodextrin, 3 times a day)
Number of subjects: 27
Study 39146397 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon receptor blockade
Number of subjects: 0
Study 39146526 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic propulsion
Number of subjects: 82
Study 39146526 — intervention group
Group type: COMPARATOR
Intervention: Observation (control)
Number of subjects: 82
Study 39146562 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep lotion (0.24 ± 0.01% melatonin)
Number of subjects: 63
Study 39146562 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep lotion
Number of subjects: 63
Study 39146562 — intervention group
Group type: COMPARATOR
Intervention: Placebo lotion
Number of subjects: 63
Study 39146624 — intervention group
Group type: EXPERIMENTAL
Intervention: LUNG-TRAC model (blood-based assay for ctDNA methylation)
Number of subjects: 245
Study 39146670 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolbetuximab plus chemotherapy (mFOLFOX6; CAPOX)
Number of subjects: 1072
Study 39146670 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 1072
Study 39146670 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolbetuximab plus chemotherapy
Number of subjects: 1072
Study 39146756 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine
Number of subjects: 69
Study 39146756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 39146801 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics administered before skin incision
Number of subjects: 28
Study 39146801 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics administered after umbilical cord clamping
Number of subjects: 28
Study 39146944 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose hyperfractionated radiotherapy (54 Gy in 30 fractions)
Number of subjects: 224
Study 39146944 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose radiotherapy (45 Gy in 30 fractions)
Number of subjects: 224
Study 39146946 — intervention group
Group type: EXPERIMENTAL
Intervention: VLA1553 vaccination
Number of subjects: 363
Study 39146951 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant pembrolizumab (200 mg IV every 3 weeks for up to 18 doses)
Number of subjects: 1019
Study 39146951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1019
Study 39146951 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant pembrolizumab vs Placebo
Number of subjects: 1019
Study 39147194 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical rSm29 (10 µg) plus Meglumine antimoniate (MA) (20 mg/kg/weight) for 20 days
Number of subjects: 91
Study 39147194 — intervention group
Group type: COMPARATOR
Intervention: Meglumine antimoniate (MA) (20 mg/kg/weight) for 20 days
Number of subjects: 91
Study 39147194 — intervention group
Group type: COMPARATOR
Intervention: Topical placebo plus Meglumine antimoniate (MA) (20 mg/kg/weight) for 20 days
Number of subjects: 91
Study 39147306 — intervention group
Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA)
Number of subjects: 108
Study 39147306 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbol Digit Modalities Test (SDMT)
Number of subjects: 108
Study 39147306 — intervention group
Group type: EXPERIMENTAL
Intervention: Two Simple Questions (TSQ)
Number of subjects: 108
Study 39147306 — intervention group
Group type: EXPERIMENTAL
Intervention: Informant Questionnaire on Cognitive Decline in the Elderly-Cardiac Arrest (IQCODE-CA)
Number of subjects: 108
Study 39147306 — intervention group
Group type: EXPERIMENTAL
Intervention: MoCA and SDMT combined
Number of subjects: 108
Study 39147364 — intervention group
Group type: EXPERIMENTAL
Intervention: Odronextamab
Number of subjects: 128
Study 39147573 — intervention group
Group type: EXPERIMENTAL
Intervention: PTAS (Percutaneous Transluminal Angioplasty and Stenting)
Number of subjects: 809
Study 39147573 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment alone
Number of subjects: 809
Study 39147573 — intervention group
Group type: EXPERIMENTAL
Intervention: PTAS
Number of subjects: 809
Study 39147695 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveillance biopsies
Number of subjects: 0
Study 39147695 — intervention group
Group type: EXPERIMENTAL
Intervention: New biomarkers (blood gene expression profiles, donor derived-cell free DNA, urine gene expression profiles, urinary cytokines, chemokines, and metabolomics)
Number of subjects: 0
Study 39147695 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum creatinine
Number of subjects: 0
Study 39147903 — intervention group
Group type: EXPERIMENTAL
Intervention: Incubator oxygen
Number of subjects: 25
Study 39147903 — intervention group
Group type: COMPARATOR
Intervention: Nasal cannula oxygen
Number of subjects: 25
Study 39147988 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol administration
Number of subjects: 14
Study 39147992 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Mallampati classification score
Number of subjects: 3243
Study 39147992 — intervention group
Group type: COMPARATOR
Intervention: Best visible Mallampati score
Number of subjects: 3243
Study 39148008 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF Ultra® testing from sputum, stool, and urine samples, with additional urine LF-LAM testing in the first 24 hours after hospital admission.
Number of subjects: 100
Study 39148008 — intervention group
Group type: COMPARATOR
Intervention: WHO standard of care recommendations.
Number of subjects: 100
Study 39148018 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone oil removal after rhegmatogenous retinal detachment surgery
Number of subjects: 161
Study 39148018 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous unsuccessful surgery
Number of subjects: 161
Study 39148018 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone oil tamponade ≤ 3 months
Number of subjects: 161
Study 39148018 — intervention group
Group type: COMPARATOR
Intervention: 360° laser retinopexy and concomitant air or gas tamponade
Number of subjects: 161
Study 39148020 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS patients
Number of subjects: 0
Study 39148020 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls (HCs)
Number of subjects: 0
Study 39148031 — intervention group
Group type: EXPERIMENTAL
Intervention: SII-PNI score
Number of subjects: 181
Study 39148083 — intervention group
Group type: EXPERIMENTAL
Intervention: Trait impulsivity (measured using the Barratt Impulsiveness Scale 11)
Number of subjects: 48377
Study 39148083 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor impulsivity subfactor
Number of subjects: 48377
Study 39148083 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention impulsivity subfactor
Number of subjects: 48377
Study 39148083 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-planning impulsivity subfactor
Number of subjects: 48377
Study 39148094 — intervention group
Group type: EXPERIMENTAL
Intervention: BACK-Standard (BACK-S)
Number of subjects: 0
Study 39148094 — intervention group
Group type: EXPERIMENTAL
Intervention: BACK-Enhanced (BACK-E)
Number of subjects: 0
Study 39148094 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 39148102 — intervention group
Group type: EXPERIMENTAL
Intervention: Carriers of deleterious DPYD variants (c.1670C>T, c.1913T>C, c.1925T>C, c.506delC, c.731A>C, c.1740+1G>T, c.763-2A>G)
Number of subjects: 986
Study 39148102 — intervention group
Group type: COMPARATOR
Intervention: DPYD exon sequencing and GWAS analysis
Number of subjects: 986
Study 39148107 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus 1 mg/m²/day with dose adjustments during a two-week titration period to maintain trough blood concentrations between 5 and 10 ng/ml (maximum dose 2 mg)
Number of subjects: 1738
Study 39148107 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 1738
Study 39148127 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR-50 (50% incremental peak power output and 50% limb occlusion pressure)
Number of subjects: 24
Study 39148127 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR-50
Number of subjects: 24
Study 39148127 — intervention group
Group type: COMPARATOR
Intervention: TRA-65 (65% incremental peak power output without occlusion)
Number of subjects: 24
Study 39148128 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous magnesium sulphate administration
Number of subjects: 530
Study 39148128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 530
Study 39148307 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuminoids (Meriva) 500 mg po bid for 180 days
Number of subjects: 0
Study 39148307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39148430 — intervention group
Group type: COMPARATOR
Intervention: MBL949 (0.03 to 20 mg, single ascending dose)
Number of subjects: 191
Study 39148430 — intervention group
Group type: COMPARATOR
Intervention: MBL949 (biweekly dosing for 14 weeks)
Number of subjects: 191
Study 39148430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study 39148533 — intervention group
Group type: EXPERIMENTAL
Intervention: NanoBEO
Number of subjects: 29
Study 39148533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 39148822 — intervention group
Group type: EXPERIMENTAL
Intervention: GPT-4 via ChatGPT Plus in addition to conventional resources
Number of subjects: 92
Study 39148822 — intervention group
Group type: COMPARATOR
Intervention: Conventional resources alone
Number of subjects: 92
Study 39148822 — intervention group
Group type: EXPERIMENTAL
Intervention: GPT-4 via ChatGPT Plus
Number of subjects: 92
Study 39148822 — intervention group
Group type: EXPERIMENTAL
Intervention: GPT-4-augmented physicians
Number of subjects: 92
Study 39148905 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib in combination with palliative thoracic radiotherapy (RT)
Number of subjects: 114
Study 39148905 — intervention group
Group type: COMPARATOR
Intervention: Palliative thoracic radiotherapy (RT) alone
Number of subjects: 114
Study 39148906 — intervention group
Group type: EXPERIMENTAL
Intervention: PIPAC with cisplatin 10.5 mg/m²
Number of subjects: 4
Study 39148964 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical microencapsulated benzoyl peroxide (E-BPO) for eight weeks
Number of subjects: 31
Study 39148964 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream for eight weeks
Number of subjects: 31
Study 39148964 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical microencapsulated benzoyl peroxide (E-BPO) for four weeks after vehicle cream
Number of subjects: 31
Study 39148964 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream for four weeks after E-BPO
Number of subjects: 31
Study 39149012 — intervention group
Group type: EXPERIMENTAL
Intervention: taTME (transanal total mesorectal excision)
Number of subjects: 524
Study 39149012 — intervention group
Group type: COMPARATOR
Intervention: laTME (laparoscopic total mesorectal excision)
Number of subjects: 524
Study 39149465 — intervention group
Group type: EXPERIMENTAL
Intervention: TFC+ISF+P4P
Number of subjects: 428
Study 39149465 — intervention group
Group type: COMPARATOR
Intervention: TFC+ISF
Number of subjects: 428
Study 39149465 — intervention group
Group type: EXPERIMENTAL
Intervention: P4P
Number of subjects: 428
Study 39149468 — intervention group
Group type: EXPERIMENTAL
Intervention: WU-CART-007 (900 million cells) with enhanced lymphodepletion
Number of subjects: 26
Study 39149474 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (12 weeks treatment)
Number of subjects: 17
Study 39149474 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 17
Study 39149645 — intervention group
Group type: EXPERIMENTAL
Intervention: Online training
Number of subjects: 47
Study 39149645 — intervention group
Group type: COMPARATOR
Intervention: In-person training
Number of subjects: 47
Study 39149709 — intervention group
Group type: EXPERIMENTAL
Intervention: Subretinal injection of cord blood platelet-rich plasma (CB-PRP)
Number of subjects: 13
Study 39149709 — intervention group
Group type: COMPARATOR
Intervention: Control (fellow eye without treatment)
Number of subjects: 13
Study 39150084 — intervention group
Group type: EXPERIMENTAL
Intervention: AF progression (transition from paroxysmal AF to persistent AF)
Number of subjects: 718
Study 39150084 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous hospitalization for heart failure
Number of subjects: 718
Study 39150084 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial diameter (per 5-mm increase)
Number of subjects: 718
Study 39150084 — intervention group
Group type: EXPERIMENTAL
Intervention: AF progression
Number of subjects: 718
Study 39150169 — intervention group
Group type: EXPERIMENTAL
Intervention: Collegial midwifery assistance
Number of subjects: 1762
Study 39150169 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1762
Study 39150169 — intervention group
Group type: EXPERIMENTAL
Intervention: OASI (Obstetric Anal Sphincter Injury)
Number of subjects: 1762
Study 39150169 — intervention group
Group type: EXPERIMENTAL
Intervention: Major second-degree tears
Number of subjects: 1762
Study 39150169 — intervention group
Group type: EXPERIMENTAL
Intervention: Episiotomy
Number of subjects: 1762
Study 39150169 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor second-degree tears
Number of subjects: 1762
Study 39150488 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CCTA)
Number of subjects: 106
Study 39150490 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) monotherapy for 52 weeks
Number of subjects: 17
Study 39150711 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant (15 mg) taken at bedtime for up to 7 days
Number of subjects: 203
Study 39150711 — intervention group
Group type: COMPARATOR
Intervention: Placebo taken at bedtime for up to 7 days
Number of subjects: 203
Study 39150750 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable devices collecting physiological parameters
Number of subjects: 550
Study 39150761 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth care experiential learning program (6 sessions)
Number of subjects: 92
Study 39150761 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 92
Study 39150858 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital home-based cardiac rehabilitation program (RecoveryPlus.Health) using telehealth and mHealth modalities
Number of subjects: 75
Study 39150859 — intervention group
Group type: EXPERIMENTAL
Intervention: CSL346 (Vascular Endothelial Growth Factor-B Blockade)
Number of subjects: 0
Study 39150859 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 39151033 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy with oral phosphate salts and active vitamin D
Number of subjects: 514
Study 39151033 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with nephrocalcinosis
Number of subjects: 514
Study 39151033 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults with nephrocalcinosis
Number of subjects: 514
Study 39151112 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib for ≥six months
Number of subjects: 47
Study 39151165 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel module-based psychological treatment based on cognitive behavioral therapy and family therapy
Number of subjects: 0
Study 39151419 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone treatment
Number of subjects: 33
Study 39151419 — intervention group
Group type: EXPERIMENTAL
Intervention: PSMA-/FDG+ lesions at week 13
Number of subjects: 33
Study 39151421 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy (up to 4 cycles of neoadjuvant chemotherapy followed by 3 cycles of adjuvant intravenous carboplatin/weekly paclitaxel/pembrolizumab, and maintenance pembrolizumab until progression or toxicity, maximum 20 cycles)
Number of subjects: 31
Study 39151421 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy (specifically for patients with PD-L1 combined positive score (CPS) ≥10)
Number of subjects: 31
Study 39151421 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy (specifically for patients with PD-L1 CPS <10)
Number of subjects: 31
Study 39151421 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 31
Study 39151420 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing bilirubin (Z,Z) at ages 1.5-3 years
Number of subjects: 0
Study 39151420 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 6 bilirubin (Z,Z)
Number of subjects: 0
Study 39151420 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing bilirubin (E,E), bilirubin (Z,Z), and biliverdin at ages 1.5-3 years
Number of subjects: 0
Study 39151436 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence-guided bowel anastomosis (FGBA) with 5 mg of ICG by 2 mL intravenous bolus.
Number of subjects: 931
Study 39151436 — intervention group
Group type: COMPARATOR
Intervention: Conventional bowel anastomosis (CBA).
Number of subjects: 931
Study 39151436 — intervention group
Group type: EXPERIMENTAL
Intervention: Both FGBA and CBA groups.
Number of subjects: 931